Mitral Regurgitation in Obstructive Hypertrophic Cardiomyopathy: Insight from the VALOR-HCM Study

Paul C. Cremer*, Jeffrey B. Geske, Anjali Owens, Wael A. Jaber, Serge C. Harb, Sara Saberi, Andrew Wang, Mark Sherrid, Srihari S. Naidu, Hartzell V. Schaff, Nicholas G. Smedira, Qiuqing Wang, Kathy Wolski, Kathy L. Lampl, Amy J. Sehnert, Steven E. Nissen, Milind Y. Desai

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

5 Scopus citations
Original languageEnglish (US)
Pages (from-to)994-996
Number of pages3
JournalJACC: Cardiovascular Imaging
Volume17
Issue number8
DOIs
StatePublished - Aug 2024

Funding

The VALOR-HCM study was funded by Bristol Myers Squibb. The Cleveland Clinic Center for Clinical (C5) Research received funding for the trial, but none of the C5 Research personnel received any honoraria from the sponsor. Dr Desai serves as a consultant for MyoKardia (now MyoKardia Inc, a wholly owned subsidiary of Bristol Myers Squibb) and Medtronic. Drs Geske, Owens, Saberi, and Naidu serve as consultants for Bristol Myers Squibb and Cytokinetics. Dr Wang serves as a consultant for Bristol Myers Squibb and Cytokinetics; is on the speakers bureau for Bristol Myers Squibb; and has received research grants from Bristol Myers Squibb and Cytokinetics. Dr Smedia serves as a consultant for Bristol Myers Squibb. Drs Lampl and Sehnert are employees of MyoKardia Inc, a wholly owned subsidiary of Bristol Myers Squibb; and Dr Sehnert discloses Bristol Myers Squibb stock and stock grants.

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this